In Vitro Diagnostics Quality Control Market To Forsee Commendable Growth, Due To An Increasing Number Of Accredited Clinical Laboratories

  

 

The global IVD quality control market size is expected to reach USD 1.24 billion by 2026, according to a new report by Grand View Research, Inc. The market is projected to witness a CAGR of 4.1% over the forecast period. Continually evolving technology-oriented changes in the diagnostics field and growing need to ensure patient safety necessitate the implementation of quality assurance programs in various medical disciplines including radiology and Point-of-Care (PoC) devices. Patients rely on self-testing IVD devices for long-term disease management and hence it is important for such devices to be checked, in terms of result reproducibility and validity, to guarantee patient safety.

 

Rising number of certified clinical laboratories offering dependable IVD-based diagnostic services directly correlates with increased patient confidence, thus driving the market. In addition to quality assessments, amendments to the regulatory framework are made intermittently to enhance the existing standards with the main objective of safeguarding qualitative superiority of the diagnostic services. In May 2016, the European Union passed an agreement to update the pre-existing regulations pertaining to IVD devices, wherein the updates were in concern with raising the patient safety levels, particularly for disabled persons. The presence of third-party agencies for independent assessment of the IVD devices is expected to elevate the current safety standards, which will drive the In Vitro Diagnostics (IVD) Quality Control market further.

 

Further key findings from the study suggest:

• In 2018, the clinical chemistry was the second-largest application segment of the global IVD market, in terms of market share
• Demand for preventive medicine and rapid transformation of clinical laboratories into highly automated and efficient businesses are some of the factors for the segment’s growth
• Molecular diagnostics is projected to be the fastest-growing segment due to increasing technical complexity of molecular diagnostic testing and need for quality evaluation to ensure standards
• These tests are of prime importance as the outcomes enable healthcare practitioners make critical treatment decisions
• Hospitals was the largest segment in 2018 due to the presence of advanced technology-based devices like Next Generation Sequencing (NGS) and microarrays, and rising applications of the optimized quality-control procedures
• North America was the dominant regional market in 2018 due to the presence of over 150,000 registered diagnostics labs and is likely to maintain the dominance throughout the forecast years
• Siemens Healthcare GmbH; Roche Diagnostics; Alere, Inc.; Abbott Laboratories, Inc.; Qiagen N.V.; Bio-Rad Laboratories, Inc.; Quidel Corp.; Becton, Dickinson and Company; bioMerieux, Inc.; Sysmex Corp.; Sero AS; and Thermo Fisher Scientific, Inc. are some of the key companies in the global market

 

The global In Vitro Diagnostics (IVD) and IVD quality control market combines to account for USD 112.79 billion in revenue in 2021, which is expected to reach USD 114.73 billion by 2030, growing at a cumulative rate of 0.2% over the forecast period. The combination bundle is designed to provide a holistic view of these highly dynamic market spaces.

 

In Vitro Diagnostics Quality Control Market Segmentation:

 

Grand View Research has segmented the global IVD quality control market on the basis of application, type, end use, and region:

IVD Quality Control Application Outlook (Revenue, USD Million, 2014 - 2026)

• Immunochemistry
• Hematology
• Clinical Chemistry
• Molecular Diagnostics
• Coagulation
• Microbiology
• Others

 

IVD Quality Control Type Outlook (Revenue, USD Million, 2014 - 2026)

• Quality Control 
  • Quality Controls, by Type
    • Plasma-based Control
    • Serum-based Control
    • Whole Blood-based Control
    • Others
  • Quality Controls, by Application
    • Immunochemistry
    • Hematology
    • Clinical Chemistry
    • Molecular Diagnostics
    • Coagulation
    • Microbiology
    • Others
  • Quality Assurance Services
    • Immunochemistry
    • Hematology
    • Clinical Chemistry
    • Molecular Diagnostics
    • Coagulation
    • Microbiology
    • Others
  • Data Management
    • Clinical Chemistry
    • Immunochemistry
    • Hematology
    • Molecular Diagnostics
    • Coagulation
    • Microbiology
    • Others

 

IVD Quality Control End Use Outlook (Revenue, USD Million, 2014 - 2026)

• Hospitals
• Laboratories
• Home-care
• Others

 

IVD Quality Control Regional Outlook (Revenue, USD Million, 2014 - 2026)

• North America
  • S.
  • Canada
• Europe
  • K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Singapore
  • Australia
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia

 

Order a free sample of this Intelligence study @ https://www.grandviewresearch.com/sector-report/in-vitro-diagnostics-ivd-quality-control-industry-data-book/request/rs1 

 

Wearable Breast Pumps Market To Show Astonishing CAGR, Based On Growing Consumer Awareness Till 2030

 

 

 

The global wearable breast pumps market is anticipated to reach USD 975.5 million by 2030, registering a CAGR of 8.21%, according to a new report by Grand View Research, Inc. Favorable reimbursement policies, and increasing patient disposable income are further anticipated to propel the demand for wearable breast pumps.

 

The decreasing infant mortality rate is supplementing the growth of the market. For instance, according to Knoema, the infant mortality rate in Japan fell from 13.4 deaths per 1,000 births in 1970, to 1.80 deaths in 2019. Similarly, as per Statistics Canada, the infant death rate has fallen from 4.8 per 1,000 in 2018 to 4.5 in 2020 in Canada. Such instances are expected to increase the demand for wearable breast pumps, thereby, propelling the market growth over the forecast period.

 

Increase in women’s employment rate is expected to be a high impact rendering driver of the market. For instance, as per International Labor Organization, the female working population in Australia has touched 60%. Similarly, as per the similar source, the female employment rate in high income countries is estimated to be 53%, whereas, the same in low income and upper middle-income countries is calculated to be 56% and 55% respectively. Working women have a relatively high disposable income, as a result can help the market impel.

 

The presence of various e-commerce sites offering wearable breast pumps will further aid in the sales of the products through these sales channels in the forecast period. Willow, Elvie, Medela, and Amazon, are few prominent e-commerce sites that offers substantial discounts, and prompt customer service on various wearable breast pumps, owing to which individuals prefer to shop from online sites.

 

The decline in the COVID-19 population is anticipated to boost market growth. Recently, many companies have called back their employees to work from office. For instance, companies such as Sun Pharmaceuticals, Biocon, and JP Morgan are planning to start work from office. This will surge the need for wearable breast pumps for working women, thereby propelling the market growth in post-COVID-19 time. Similarly, to cope with the rising demand many companies are launching new products and expanding their geographic presence. For instance, in February 2021, Medela LLC launched a new category expansion and breast care products with an aim of meeting customer requirements. This was expected to expand the customer base of the company.

 

Wearable Breast Pumps Market Report Highlights

• Based on components, the wearable pumps segment dominated the market with a share of 57.84% in 2021 and is also expected to witness the fastest growth rate owing to its increasing demand over the forecast period. As lactating mothers are becoming more aware of the importance and benefits of breastfeeding.
• On the basis of technology, the battery powered wearable breast pump segment dominated the market with a share of 48.64% in 2021. This can be credited to their lightweight and compact designs. Moreover, women can also easily stash them into their bags and are barely noticeable.
• North America dominated the market with the highest revenue share of 52.62% in 2021 owing to a rise in women’s employment rate in the U.S. and supportive reimbursement policies for wearable breast pumps.

 

Breast Pump and Breastfeeding Accessories Market Size was valued at USD 4.06 Billion in 2021 and is projected to expand at a CAGR of 7.8% during 2022 to 2030.

 

Wearable Breast Pumps Market Segmentation

Grand View Research has segmented the global wearable breast pumps market based on component, technology, and region:

 

Global Wearable Breast Pumps Component Outlook (Revenue, USD Million, 2018 - 2030)
• Wearable Pumps
• Accessories

 

Global Wearable Breast Pumps Product Technology Outlook (Revenue, USD Million, 2018 - 2030)
• Manual Wearable Breast Pumps
• Battery Operated Wearable Breast Pumps
• Smart Wearable Breast Pumps

 

Global Wearable Breast Pumps Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
o U.S.
o Canada

• Europe
o U.K.
o Germany
o France
o Italy
o Spain

• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea

• Latin America
o Mexico
o Brazil
o Argentina
o Colombia

• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE

 

Order a free sample of this Breast Pump and Breastfeeding Accessories Industry Data Book @ https://www.grandviewresearch.com/sector-report/breast-pump-breastfeeding-accessories-industry-data-book/request/rs1

 

List of Key Players in Wearable Breast Pumps Market
• Medela AG
• Ameda, Inc.
• Willow Innovations, Inc.
• Philips
• Elvie (Chiaro Component Ltd)
• Freemie
• BabyBuddha Products, LLC
• Spectra
• iAPOY
• Lavie Mom

 

 

In Vitro Diagnostics Market To Rise Up At Exponential Growth, Owing To Development Of Automated IVD Systems For Laboratories And Hospitals

  

 

The global In vitro diagnostics market size is expected to reach USD 113.38 billion by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 0.2% over the forecast period driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users.

 

These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely.

 

In Vitro Diagnostics Market Report Highlights

• Molecular diagnostics is anticipated to grow at the fastest CAGR from 2022 to 2030 owing to the rising adoption and usage rate
• Reagents held the largest market share owing to the surge in demand for genetic testing and enhanced availability of technologically advanced diagnostic tests in lower and middle-income countries with unmet clinical needs
• The infectious diseases application segment held the largest market share owing to the large volume of testing for infectious diseases globally
• North America dominated the global market in 2021 owing to the high demand for novel technologies, a large pool of key players, high prevalence of diseases, and advanced healthcare infrastructure

 

The global In Vitro Diagnostics (IVD) and IVD quality control markets combine to account for USD 112.79 billion in revenue in 2021, which is expected to reach USD 114.73 billion by 2030, growing at a cumulative rate of 0.2% over the forecast period.

 

In Vitro Diagnostics Market Segmentation

 

Grand View Research has segmented the global in vitro diagnostics market based on product, technology, application, end-use, test location, and region:

 

IVD Product Outlook (Number of Instruments Installed in Thousands, Number of Reagents Sold in Millions; Revenue, USD Million, 2018 - 2030)
• Instruments
• Reagents
• Services

 

IVD Technology Outlook (Number of Instruments Installed in Thousands, Number of Reagents Sold in Millions; Revenue, USD Million, 2018 - 2030)

• Immunoassay
o Instruments
o Reagents
o Services

• Hematology
o Instruments
o Reagents
o Services

• Clinical Chemistry
o Instruments
o Reagents
o Services

• Molecular Diagnostics
o Instruments
o Reagents
o Services

• Coagulation
o Instruments
o Reagents
o Services

• Microbiology
o Instruments
o Reagents
o Services

• Others
o Instruments
o Reagents
o Services

 

IVD Application Outlook (Revenue, USD Million, 2018 - 2030)
• Infectious Disease
• Diabetes
• Oncology
• Cardiology
• Nephrology
• Autoimmune Disease
• Drug Testing
• Others

 

IVD End-use Outlook (Number of Instruments Installed in Thousands, Number of Reagents Sold in Millions; Revenue, USD Million, 2018 - 2030)
• Hospitals
• Laboratories
• Home Care
• Others

 

IVD Test Location Outlook (Revenue, USD Million, 2018 - 2030)
• Point of Care
• Home Care
• Others

 

IVD Regional Outlook (Number of Instruments Installed in Thousands, Number of Reagents Sold in Millions; Revenue, USD Million, 2018 - 2030) 

• North America
  • S.
  • Canada
• Europe
  • K.
  • Germany
  • Spain
  • France
  • Italy
  • Russia
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Singapore
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia

 

Order a free sample of In Vitro Diagnostics And IVD Quality Control Industry Data Book @  https://www.grandviewresearch.com/sector-report/in-vitro-diagnostics-ivd-quality-control-industry-data-book/request/rs1

 

List of Key Players in In Vitro Diagnostics Market
• Abbott
• Bio-Rad Laboratories, Inc.
• Quest Diagnostics
• bioMérieux SA
• QIAGEN
• Sysmex Corp.
• Agilent Technologies

 

 

Breast Pump Market To Predict Global Expansion, Based On Rising Women's Employment Rates To 2030

 

 

 

The global breast pump market is expected to reach USD 5.20 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 8.3% from 2022 to 2030. Improving healthcare infrastructure in emerging economies, increasing global women's employment rates and the presence of favorable demographics are the key driving factors for the breast pump market. 

Moreover, the market has seen significant growth over the last few decades, owing to increasing product launches by key players, and rising R&D activities. For instance, in March 2021, the Philips Avent Double Electric Breast Pump, Advanced is the top brand of mothers and children care goods recommended by pregnant women and mothers in the U. S. It features Natural Action technology, a powerful combination of suction and nipple stimulation that simulates the distinctive wave-like tongue motion that occurs when the baby sucks. This technology initiates the milk flow faster than previous models, enabling moms to express their milk more effectively.

Similarly, in October 2021, Willow also launched its Perfect Pumping Bra, developed by The Dairy Fairy. Willow pump bra was designed to provide moms with exceptional comfort, support, and a perfect fit, helping them to have the best possible pumping experience. The appropriate fit can help boost the mother's milk flow while using wearable breast pumps. Adjustable straps, a customizable mesh panel, beautiful lace embellishments, and a patent-pending double extender clip characterize the Willow Perfect Pumping Bra. Furthermore, the wire-free bra's luxurious fabric is machine washable and elastic while still being designed to secure the Willow pump for an ideal pumping experience. As a result, product launches with additional benefits are expected to increase market growth for these breast pumps over the projection period.

 

Breast Pump Market Report Highlights: 

• In terms of product, closed system segment held the largest market share of 65.3% in 2021 and is expected to witness the fastest growth over the forecast period due to its several benefits and high adoption, as compared to the open system. 

• In terms of technology, electric pumps segment held the largest share in 2021 owing to its flexibility and ease of use. 

• In terms of application, hospital grade segment held the largest market share in 2021, owing to the increasing number of hospitals and rising healthcare expenditure. 

• North America is expected to dominate the market growth over the forecast period owing to the rising women's employment and large presence of key players operating in the market.  

Breast Pump and Breastfeeding Accessories Market Size was valued at USD 4.06 Billion in 2021 and is projected to expand at a CAGR of 7.8% during 2022 to 2030. 

 

Breast Pump Market Segmentation

 

Grand View Research has segmented the global breast pump market report on the basis of product, technology, application, and region:

 

Breast Pump Market - Product Outlook (Revenue, USD Million, 2018 - 2030) 

• Open System
• Closed System

 

Breast Pump Market - Technology Outlook (Revenue, USD Million, 2018 - 2030) 

• Manual Pumps
• Battery Powered Pumps
• Electric Pumps

 

Breast Pump Market - Application Outlook (Revenue, USD Million, 2018 - 2030) 

• Personal Use
• Hospital Grade

 

Breast Pump Market - Regional Outlook (Revenue, USD Million, 2018 - 2030) 

• North America
  • S.
  • Canada
• Europe
  • K.
  • Germany
  • France
  • Italy
  • Spain
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE

 

List of Key Players in Breast Pump Market 

• Ameda (Magento, Inc.)
• Hygeia Health
• Medela AG
• Koninklijke Philips N.V.
• Lansinoh Laboratories, Inc.
• Pigeon Corporation
• Motif Medical
• Chiaro Technology Limited (Elvie)
• Willow Innovations, Inc.
• Spectra Baby USA 

 

Request free sample copy of Breast Pump and Breastfeeding Accessories Industry Data Book @  https://www.grandviewresearch.com/sector-report/breast-pump-breastfeeding-accessories-industry-data-book/request/rs1

Hemoglobinopathies Market Is Estimated To Grow Up, Due To Rising Prevalence Of Conditions Such As Sickle Cell Disease (SCD) And Thalassemia

 

 

 

Hemoglobinopathies Industry Overview

The global hemoglobinopathies market size is expected to reach USD 15.7 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 10.8% from 2021 to 2028. Increasing awareness regarding hemoglobinopathies and government initiatives to diagnose the diseases at an early stage are expected to propel the market growth over the forecast period. Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.

 

Hemoglobinopathies Market Segmentation

Grand View Research has segmented the global hemoglobinopathies market on the basis of type, diagnosis, therapy, and region:

 

Based on the Type Insights, the market is segmented into Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants.

• The sickle cell disease segment held the largest share of 56.6% in 2020 and is expected to grow at the fastest rate during the forecast period.
• This is attributed to growing initiatives by biopharmaceutical companies and nonprofit organizations focused on improving access to SCD treatment. Furthermore, sickle cell disease affects around 300,000 newborns annually. An estimated 10% to 40% of the individuals in many African countries are carriers of sickle cell gene, which has resulted in a prevalence of around 2% in these countries.
• The thalassemia segment is further sub-segmented into alpha-thalassemia and beta-thalassemia. Globally, 5% of the total population are carriers of alpha-thalassemia and around 1.5% of the population have beta-thalassemia traits. India has the maximum number of thalassemia carriers in the world.

 

Based on the Diagnosis Insights, the market is segmented into Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants.

• The sickle cell disease diagnosis segment dominated the market and accounted for more than 50.0% share in 2020 owing to high diagnostic rates in North America and Europe.
• Blood tests are most widely used for the diagnosis of SCD in patients. Moreover, the introduction of newborn baby screening programs for sickle cell disease in countries, such as the U.S., France, and Italy, will drive the segment at the fastest rate.
• The thalassemia diagnosis segment is estimated to grow at a significant rate over the forecast period. The introduction of technologically advanced, rapid, and user-friendly diagnostic tests is driving the segment.

 

Based on the Therapy Insights, the market is segmented into Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants.

• The sickle cell disease segment held the largest revenue share of 59.4% in 2020. Extensive research has been carried out to develop novel therapies for treating the disorder, which is contributing to the segment growth.
• Gene therapy has emerged as a promising treatment option for managing the disorder as it targets the underlying genetic cause of the condition through one-time administration and reduces the need for patients to undertake blood transfusions.
• Blood transfusion is considered to be the first line of treatment for hemoglobin disorders. The frequency of blood transfusion is higher in thalassemia cases as compared to other hemoglobinopathies. The transfusion is done every 3 to 4 weeks to help maintain the normal level of blood components.
• Bone marrow transplant (BMT) therapy is expected to expand at a significant growth rate over the forecast period. BMT is often used when blood transfusion and other therapies fail. BMT is reported to be effective when performed in the early stages of disease progression. 

 

Hemoglobinopathies Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

Market players are taking up various initiatives, such as mergers & acquisitions, partnerships, collaborations, and extensive R&D, in order to gain a greater share in the market.

Some prominent players in the global hemoglobinopathies market include

• Sangamo Therapeutics, Inc.
• Global Blood Therapeutics, Inc.
• bluebird bio, Inc.
• Emmaus Life Sciences Inc.
• Pfizer, Inc.
• Novartis AG
• Prolong Pharmaceuticals, LLC
• Bioverativ Inc.
• Gamida Cell

 

Order a free sample PDF of the Hemoglobinopathies Market Intelligence Study, published by Grand View Research.

 

 

Intravenous Immunoglobulin Market To Rise Up, Due To Increasing Adoption Of Intravenous Immunoglobulin (IVIG) Treatments And Rising Use Of Off-Label Indications

  

 

 

Intravenous Immunoglobulin Industry Overview

 

The global intravenous immunoglobulin market size is expected to reach USD 21.1 billion by 2030, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 7.3% from 2022 to 2030. The increasing prevalence of immunodeficiency diseases, coupled with the adoption of intravenous immunoglobulin (IVIG) therapies, is expected to fuel market growth over the forecast period. In addition, increasing off-label use of immunoglobulin and investments in the healthcare sector are factors propelling the market growth. Moreover, increasing incidences of bleeding disorders and the growing geriatric population are the factors contributing to the industry growth.

 

Intravenous Immunoglobulin Market Segmentation

Grand View Research has segmented the global intravenous immunoglobulin market on the basis of application, distribution channel, and region:

 

Based on the Application Insights, the market is segmented into Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome, Others.

• In 2021, immunodeficiency diseases dominated the market with a revenue share of over 20.0% owing to the increasing incidence of primary and acquired immunodeficiency diseases (PID & AID). PID & AID need to be treated with IV antibiotics to clear the infections. IVIG replacement therapy is the best available alternative for the treatment of immunodeficiency diseases. 
• The chronic inflammatory demyelinating polyneuropathy segment held the second-largest share in 2021. It is usually found in patients with diabetes mellitus. The treatment of CIDP involves the use of immunosuppressive drugs, steroids, and plasmapheresis. IVIG is an effective and long-lasting alternative to these methods.
• Hypogammaglobulinemia accounted for the third-largest revenue share in 2021. This can be attributed to the increasing incidences of primary immunodeficiency diseases (PID) worldwide. It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs).
• The Kawasaki disease segment is expected to witness lucrative growth owing to rising incidences of Kawasaki disease in children and rising demand for IVIG procedures for its treatment. The alternative for IVIG therapy is steroids which have more side effects; hence the penetration of IVIG therapies for the treatment of Kawasaki disease is expected to grow in the coming years.

 

Based on the Distribution Channel Insights, the market is segmented into Hospital Pharmacy, Specialty Pharmacy, Others.

• The hospital pharmacy segment dominated the market with a revenue share of over 55.0% in 2021 owing to the large network of hospitals and the convenient range of products that are easily accessible through hospital pharmacies.
• Moreover, the growing incidence of primary immune deficiencies, hepatitis C, and other diseases has resulted in an increment in the number of hospitalizations worldwide, expanding the customer preference for hospital pharmacies.
• Furthermore, hospitals offer fast reimbursement, treatment, and proper care to a large number of patients, enabling a surge in the prevalence of patients selecting hospital pharmacies.
• The specialty pharmacy segment is anticipated to grow significantly during the forecast period as specialty pharmacies enable easy treatment at home. Specialty drugs are an important and dynamic part of the pharmacy

 

Intravenous Immunoglobulin Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

This industry is witnessing a significant boost owing to the growing number of FDA approvals. Owing to this, a number of local and international players are investing in the IVIG business. Market players are adopting various strategies such as mergers and acquisitions, distribution, and other collaborative agreements to gain a greater share by increasing their market penetration. 

 

Some prominent players in the global intravenous immunoglobulin market include

• Biotest AG
• Baxter International Inc.
• Octapharma AG
• LFB Biotechnologies
• Grifols SA
• CSL Behring
• China Biologics Products Inc.
• Kedrion Biopharma
• BDI Pharma Inc.

 

Order a free sample PDF of the Intravenous Immunoglobulin Market Intelligence Study, published by Grand View Research.

 

Astaxanthin Market Is Expected To Rise, As Of Government Initiatives To Increase The Manufacturing Capacity

  

 

 

Astaxanthin Industry Overview

 

The global astaxanthin market size is expected to reach USD 4.75 billion by 2028, registering a CAGR of 16.8%, according to a new report by Grand View Research, Inc. Increasing adoption of dietary supplements, growing awareness among people regarding healthy lifestyle, and government initiatives to increase the manufacturing capacity are anticipated to boost the market growth. For instance, in May 2019, Algalíf Iceland ehf. received financial aid from EU’s SME Instrument program and Icelandic Centre for Research’s Technology Development Fund to expand its manufacturing capacities by adding spray dryers.

 

Astaxanthin Market Segmentation

Grand View Research has segmented the global astaxanthin market on the basis of source, product, application, and region:

 

Based on the Product Insights, the market is segmented into Dried Algae Meal or Biomass, Oil, Softgel, Liquid, Others.

• The dried algae meal or biomass segment dominated the global market in 2020 with a revenue share of over 25% and is anticipated to maintain its dominance over the forecast period.
• The use of biomass for the production of other formulations, the requirement of less downstream processing, high usage as animal feed, and easy bulk production are some key factors driving the segment growth. Moreover, biomass has a variety of products ranging from 1 to 5% of astaxanthin-containing products, which increase the usage of biomass in different end-use industries.
• The softgels segment is anticipated to exhibit the fastest growth rate of 17.4% during the forecast period owing to increased use in nutraceuticals and significant growth of the nutraceuticals industry.

 

Based on the Source Insights, the market is segmented into Natural, Synthetic.

• The natural source segment dominated the market in 2020 and is estimated to witness the fastest CAGR of 19.3% during the forecast period. Wide-scale availability, increased demand for natural food supplements, and higher efficacy compared to synthetic sources are key factors driving the segment growth.
• Synthetic astaxanthin is also expected to grow at a double-digit growth rate over the forecast period owing to increased demand from the aquaculture industry and availability of safe & approved products, such as Cardax, Inc.’s ZanthoSyn as an anti-inflammatory.

 

Based on the Application Insights, the market is segmented into Nutraceuticals, Cosmetics, Aquaculture &Animal Feed, Food, Others.

• The aquaculture and animal feed segment dominated the market in 2020 with a revenue share of over 47% and is anticipated to grow at a steady CAGR over the forecast period, owing to its extensive use as a feed additive.
• Moreover, a rise in the adoption of astaxanthin in the aquaculture industry for improving the quality of seafood is contributing to the segment’s significant share in the market. Key market players are developing the product containing astaxanthin as animal feed having medical benefits.
• The nutraceuticals segment is estimated to witness the fastest growth over the forecast period owing to the superior antioxidant properties of astaxanthin as compared to other food supplements, easier availability, and a wider range of applications in the nutraceuticals industry. 

 

Astaxanthin Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

Key players are contributing to market growth by adopting various strategies, such as geographical expansion, to gain a higher market share. In addition, companies are focusing on gaining market approvals for innovative products to help in the management of different health conditions.

 

Some prominent players in the global astaxanthin market include

• CO2 GRO Inc. (BlueOceanNutraSciences)
• FENCHEM
• ENEOS Corporation (JXTG Nippon Oil & Energy Corporation)
• E.I.D. – Parry (India) Limited
• MicroA
• NextFerm
• Algalif Iceland ehf
• ALGAMO

 

Order a free sample PDF of the Astaxanthin Market Intelligence Study, published by Grand View Research.

 

Veterinary Equipment And Disposables Market To Strike CAGR Of 8.8% From 2022 To 2030

 

 

Veterinary Equipment And Disposables Industry Overview

 

The global veterinary equipment and disposables market size is expected to reach USD 4.4 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.8% from 2022 to 2030. Increasing pet health expenditure and growing concern among pet owners are driving the market. Advancement in veterinary equipment and growing initiatives by the industry players are boosting the growth. Companies are investing in the expansion of their manufacturing facilities, which is expected to positively influence the revenue over the forecast period. For instance, in June 2021, Veterinary Instrumentation (VI), announced an expansion in the U.S. market. With this expansion, VI is going to bring the support of the expert team to veterinarians and more than 4,000 professional veterinary instruments in the U.S. This initiative is expected to boost the company’s growth, as it allows brand development in North America.

 

Veterinary Equipment And Disposables Market Segmentation

Grand View Research has segmented the global veterinary equipment and disposables market on the basis of product, animal type, end use, and region:

 

Based on the Product Insights, the market is segmented into Critical Care Consumables, Anesthesia Equipment, Fluid Management Equipment, Temperature Management Equipment, Rescue & Resuscitation Equipment, Research Equipment, Patient Monitoring Equipment.

• The critical care consumables segment dominated the market for veterinary equipment and disposables and held the largest revenue share of over 33.0% in 2021.
• The growth can be attributed to increasing usage of the consumables for various applications such as wound management, airway management, gastroenterology, reproduction, and others. Continuous development and new product launches by the industry players are bolstering the growth.
• The rescue and resuscitation equipment segment is expected to show the fastest growth over the forecast period. Managing cardiopulmonary arrest requires quick patient assessment, with immediate implementation of Cardiopulmonary Resuscitation (CPR) in cats and dogs.
• Rescue and resuscitation equipment is divided into resuscitation bags and oxygen masks. The resuscitation bags segment accounted for the largest market share of over 50.0% under the rescue and resuscitation equipment segment in 2021, owing to their immediate effectiveness in saving lives. 

 

Based on the Animal Type Insights, the market is segmented into Companion Animal, Livestock Animal.

• The companion animals segment dominated the market for veterinary equipment and disposables and accounted for the largest revenue share of over 64.0% in 2021. Growth in the companion animal population, rising emphasis on pet care, and wellness by pet owners are contributing to the growth of this segment.
• The dogs segment held the largest market share of the companion animals segment in 2021. The dominant share captured by this is a consequence of the increased number of surgeries. The growing incidence of chronic diseases in dogs is one of the major drivers for the market.
• The growing trend of pet adoption is anticipated to accelerate the growth of the market for veterinary equipment and disposables. In the last 30 years, pet ownership has increased from 56.0% to 67.0% in all households and nearly 85.0 million households have a pet, according to American Pet Products Association.
• The growing demand for better treatment and diagnostics, increasing activities in animal husbandry, and growing awareness about the care of livestock animals are some of the key drivers for livestock animal segment growth. Growing initiatives such as stray animal rescue programs and increasing usage of rescue and resuscitation equipment are boosting the revenue.

 

Based on the End-use Insights, the market is segmented into Veterinary Hospitals/Clinics, Research Institutes.

• The veterinary hospitals/clinics segment dominated the market for veterinary equipment and disposables and accounted for a revenue share of around over 82.0% in 2021. The growth can be attributed to the availability of a wide range of treatment options in veterinary hospitals and veterinary clinics.
• Various government animal welfare organizations have issued guidelines for safety practices and standards to be implemented in hospitals, which has broadened the scope for segment growth over the past few years.
• The research institutes segment is expected to show lucrative growth over the forecast period. Better critical care treatment options for small animals have triggered the demand for research activities which is expected to drive the segment over the forecast period.
• The COVID-19 pandemic has intensified research activities, while veterinary institutes are also focused on finding a solution for African swine fever and Highly Pathogenic Avian Influenza (HPAI).

 

Veterinary Equipment And Disposables Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

The market players are constantly involved in strategic initiatives such as new product launches, regional expansion, and mergers and acquisitions to gain deeper penetration.

 

Some prominent players in the global veterinary equipment and disposables market include

• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Smiths Medical, Inc.
• Nonin Medical, Inc.
• Digicare Biomedical
• Covetrus, Inc.
• B. Braun Melsungen AG
• DRE Veterinary
• Vetland Medical Sales and Services
• Midmark Corporation
• Jorgensen Labs
• Grady Medical

 

Order a free sample PDF of the Veterinary Equipment And Disposables Market Intelligence Study, published by Grand View Research.

Personal Mobility Devices Market Is Extrapolated To Rise, Due To Increasing Number Of Accidents And Trauma Cases

 

 

 

Personal Mobility Devices Industry Overview

 

The global personal mobility devices market size is expected to reach USD 29.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.3% from 2022 to 2030. The increasing R&D investments for the development of advanced mobility products and government initiatives to support reimbursement policies are some of the key factors boosting the market growth. The rising geriatric population and prevalence of chronic diseases, such as Parkinson’s, arthritis, and Alzheimer’s, are expected to drive the market over the forecast period.

 

The market is disrupted due to the COVID-19 pandemic during the second quarter of 2020 which affected the shipping and transportation of the devices. The decreasing production of these devices due to the pandemic has severely affected the industry's growth. The prices of wheelchairs and scooters have also been affected due to a decrease in the demand for the product. The market is likely to grow at a lucrative rate after the second half of 2020 as there is the ease of restrictions and an increase in the demand and requirement of the devices.

 

Personal Mobility Devices Market Segmentation

Grand View Research has segmented the global personal mobility devices market based on product and region:

 

Based on the Product Insights, the market is segmented into Walking Aids, Wheelchairs, Scooters.

• The wheelchair segment dominated the market for personal mobility devices and accounted for the largest revenue share of over 41.2% in 2021. The segment is expected to retain the leading position throughout the forecast period.
• Wheelchairs are one of the most common assistive devices used in personal mobility. United Nations provides appropriate legislation for requesting member states in supporting the development, production, distribution, and servicing of these mobility devices.
• The usage of appropriate wheelchairs enhances the quality of life, reduces common problems, such as deformities and pressure sores, and improves digestion and respiration.
• There are approximately 2 million new users every year, which translates to increased demand for wheelchairs in the country. Powered wheelchairs emerged as the largest sub-segment, in terms of revenue, in 2021.
• The increasing global geriatric population, chronic diseases, and growing adoption of powered wheelchairs are the key factors responsible for the growth of the wheelchair market.

 

Personal Mobility Devices Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

The market players are focusing on adopting various growth strategies, such as partnership and expansion of product portfolio, to retain their market position. For instance, in June 2021, Rollz international launched a new Rollz Flex 2 rollator which provides better comfort, stability, and design to the user. This rollator is among the most innovative creations of the company.

Some prominent players in the global personal mobility devices market include

• Drive DeVilbiss Healthcare
• GF Health Products, Inc.
• Invacare Corporation
• Carex Health Brands, Inc.
• Kaye Products, Inc.
• Briggs Healthcare
• Medline Industries, Inc.
• NOVA Medical Products
• Performance Health
• Rollz International

 

Order a free sample PDF of the Personal Mobility Devices Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Molecular Diagnostics Market To Boost, Based On Rising Elderly Population And Increasing Demand For Genetic Testing

 

 

 

Molecular Diagnostics Industry Overview

 

The global molecular diagnostics market size is expected to reach USD 31.9 billion by 2030, and is expected to decline at a CAGR of -1.6% from 2022 to 2030, according to a recent study by Grand View Research, Inc. The contraction in the market will be due to the decline in demand for molecular testing for COVID-19. However, factors such as the rising geriatric population and increasing demand for technologies such as NGS is expected to drive market growth.

 

Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results. Hence, the increasing prevalence of hospital-acquired infections & infectious diseases is projected to drive the market over the forecast period. Increasing incidence and awareness regarding genetic disorders is further anticipated to accelerate market growth. The miniaturization of three basic molecular assays-nanobiotechnology, biochips, and microfluidics are expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.

 

 

Molecular Diagnostics Market Segmentation

For this report, Grand View Research has segmented the global molecular diagnostics market based on product, test location, technology, application, and region:

 

Based on the Product Insights, the market is segmented into Instruments, Reagents, Others.

• The reagents segment accounted for the largest revenue share of the market in 2021.
• It is expected to maintain its dominance in upcoming years owing to its wide adoption in research and clinical settings. Standard reagents help achieve efficient and accurate results. Standardized results, improved efficiency, and cost-effectiveness are anticipated to support the market growth.
• The growing use of instruments to detect coronavirus, which was earlier developed for other infectious diseases, is anticipated to boost the market growth.

 

Based on the Test Location Insights, the market is segmented into Point-of-Care, Self-test or Over the Counter, Central Laboratories.

• Central laboratories held the largest share of the market in 2021, attributable to high procedure volumes for Covid testing in central laboratories. An increase in the number of initiatives undertaken by the government to provide various services, such as reimbursement for diagnostic tests, is another major factor anticipated to drive the market.
• There is an increasing interest in the development of molecular diagnostic platforms that can also be used in PoC settings. Therefore, various companies are designing assays & molecular diagnostic platforms for POC or near-patient testing.

 

Based on the Application Insights, the market is segmented into Oncology, Pharmacogenomics, Infectious Diseases, Genetic Testing, Neurological Disease, Cardiovascular Disease, Microbiology, Others.

• The infectious disease segment accounted for the largest revenue share of the molecular diagnostics market in 2021. The increased usage of molecular, particularly PCR tests, for the diagnosis of COVID-19 is the major reason for the dominance of this segment.
• The drawbacks of traditional testing, such as long turnaround time, poor in vitro kinetic development, difficulty in growing organisms in manually prepared culture media, and the lack of sensitivity have been offset with technological advancements, such as PCR and ISH.
• Oncology segment is expected to grow at a high CAGR during the forecast period. According to WHO, in 2020, an estimated 19.3 million new cancer cases were diagnosed globally; and about 10.0 million cancer deaths occurred in 2020.

 

Based on the Technology Insights, the market is segmented into Polymerase chain reaction (PCR), In Situ Hybridization (ISH), Isothermal Nucleic Acid Amplification Technology (INAAT), Chips and Microarrays, Mass Spectrometry, Sequencing, Transcription Mediated Amplification (TMA), Others.

• The polymerase chain reaction (PCR) segment accounted for the largest revenue share in 2021. This is attributed to its use in the detection of COVID-19 and other infectious diseases. The increasing use of high-throughput PCR technology to detect infectious diseases and genetic diseases is expected to drive market growth.
• Sequencing technologies for the molecular diagnostics market include DNA sequencing processes and emerging NGS technologies, such as sequencing platforms and RNA sequencing.
• DNA sequencing technologies are integrally linked to drug discovery, novel drug development, and personalized medicine. Companies are launching new NGS-based tests for early disease diagnosis.
• The sequence specificity of the ISH technique is a major application that helps in understanding pathogenic processes and performing molecular testing for diagnosis, monitoring, and treatment of cancer. Key applications of ISH technology include identifying and investigating mRNA expression in preserved tissue samples, using probes that are complementary to the concerned sequence, and molecular diagnosis of chromosomal integrity using Fluorescence ISH (FISH).

 

Molecular Diagnostics Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

Players such as Roche are using mergers and acquisitions strategy to enhance product capabilities and promote their product offerings. For instance, in May 2021, Roche acquired GenMark Diagnostics for USD 1.8 billion. This acquisition will help Roche expand its molecular diagnostics portfolio.

Some prominent players in the global molecular diagnostics market include

• BD
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Abbott
• Agilent Technologies, Inc.
• Danaher
• Hologic Inc. (Gen Probe)
• Illumina, Inc.
• Johnson & Johnson Services, Inc.
• Grifols, S.A.
• QIAGEN
• F. Hoffmann-La Roche, Ltd.
• Siemens Healthineers AG
• Sysmex Corporation

 

Order a free sample PDF of the Molecular Diagnostics Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.